Share Facebook Twitter LinkedIn Pinterest Email Soleno jumps 33% on drug approved to treat hyperphagia in Prader-Willi syndrome
InnovAge forecasts $1.05B-$1.085B revenue and $105M-$115M adjusted EBITDA for fiscal 2027 as it targets 5%-7.5% census growth (NASDAQ:INNV)September 9, 2026